Technology

AddToAny

Google+ Facebook Twitter Twitter

UK biomedical catalyst award

Centauri Therapeutics Ltd, a biotechnology company focused on the treatment of infectious diseases and cancer, has been awarded up to £945,000 under Innovate UK’s Biomedical Catalyst programme.

Alongside backing from the Company’s investors, this award from the UK’s innovation agency will co-fund research focused on antimicrobial resistance. The project aims to generate a clinical candidate drug against Gram-negative bacteria, which are a major cause of mortality in hospital-acquired pneumonias.

centauritherapeutics.com

Related Articles

“One-stop shops to speed up diagnosis”

"One-stop shop to speed up cancer diagnosis"

Special centres that are aimed at speeding up cancer diagnosis are being introduced across Englan

How did gonorrhoea become drug resistant?

How did gonorrhoea become drug resistant?

Mutations to the bacterium Neisseria gonorrhoea have been identified, that enable resistance to ceftriaxone, which could lead to the global spread of ceftriaxone-resistant “superbug” strains.

Gut bacteria drive autoimmune disease

Bacteria found in the small intestines of mice and humans can travel to other organs and trigger an autoimmune response, states a new paper.

Top